Introducing DCISionRT® – empowering women with breast cancer

Biological profiling for personalised treatment

What is DCISionRT®?

DCISionRT® is a new risk assessment test now available in Australia. The test looks at the likelihood of your ductal carcinoma in situ (DCIS) recurring after surgery, the risk of the disease spreading, and the impact of radiation therapy in reducing that risk.

DCISionRT assists you and your doctor to select treatment based on the biology of your tumour, in addition to the traditional clinical and pathology factors.

GenesisCare has partnered with PreludeDx to launch DCISionRT across our global network, with support from surgeons, pathology providers, and hospitals around the world.

Get in touch

For more information contact your local centre or call or email us using the details below.

1300 086 870
1300 086 870

Find a centre near you